Long-term Vaccine-induced Heterologous Protection Against H5N1 Influenza Viruses in the Ferret Model

Overview

Journal Influenza Other Respir Viruses

Publisher Wiley

Specialty Microbiology

Date 2012 Aug 18

PMID 22897930

Citations 5

Authors

Mariette F Ducatez

Ashley Webb

Jeri-Carol Crumpton

Richard J Webby

Affiliations

Soon will be listed here.

Abstract

Background: Highly pathogenic H5N1 influenza viruses reemerged in humans in 2003 and have caused fatal human infections in Asia and Africa as well as ongoing outbreaks in poultry. These viruses have evolved substantially and are now so antigenically varied that a single vaccine antigen may not protect against all circulating strains. Nevertheless, studies have shown that substantial cross-reactivity can be achieved with H5N1 vaccines. These studies have not, however, addressed the issue of duration of such cross-reactive protection.

Objectives: To directly address this using the ferret model, we used two recommended World Health Organization H5N1 vaccine seed strains - A/Vietnam/1203/04 (clade 1) and A/duck/Hunan/795/02 (clade 2.1) - seven single, double, or triple mutant viruses based on A/Vietnam/1203/04, and the ancestral viruses A and D, selected from sequences at nodes of the hemagglutinin and neuraminidase gene phylogenies to represent antigenically diverse progeny H5N1 subclades as vaccine antigens.

Results: All inactivated whole-virus vaccines provided full protection against morbidity and mortality in ferrets challenged with the highly pathogenic H5N1 strain A/Vietnam/1203/04 5 months and 1 year after immunization.

Conclusion: If an H5N1 pandemic was to arise, and with the hypothesis that one can extrapolate the results from three doses of a whole-virion vaccine in ferrets to the available split vaccines for use in humans, the population could be efficiently immunized with currently available H5N1 vaccines, while the homologous vaccine is under production.

Citing Articles

Pandemic preparedness through vaccine development for avian influenza viruses.

Cargnin Faccin F, Perez D Hum Vaccin Immunother. 2024; 20(1):2347019.

PMID: 38807261 PMC: 11141480. DOI: 10.1080/21645515.2024.2347019.

The Quest for a Truly Universal Influenza Vaccine.

Jang Y, Seong B Front Cell Infect Microbiol. 2019; 9:344.

PMID: 31649895 PMC: 6795694. DOI: 10.3389/fcimb.2019.00344.

Avian Influenza A Virus Pandemic Preparedness and Vaccine Development.

de Vries R, Herfst S, Richard M Vaccines (Basel). 2018; 6(3).

PMID: 30044370 PMC: 6161001. DOI: 10.3390/vaccines6030046.

Post-exposure treatment with whole inactivated H5N1 avian influenza virus protects against lethal homologous virus infection in mice.

Hagan M, Ranadheera C, Audet J, Morin J, Leung A, Kobasa D Sci Rep. 2016; 6:29433.

PMID: 27405487 PMC: 4942574. DOI: 10.1038/srep29433.

Quantitative measurement of influenza virus replication using consecutive bronchoalveolar lavage in the lower respiratory tract of a ferret model.

Lee D, Kim J, Lee J, Chung W, Park J, Lee Y J Vet Sci. 2014; 15(3):439-42.

PMID: 24690606 PMC: 4178147. DOI: 10.4142/jvs.2014.15.3.439.

References

Roti M, Yang J, Berger D, Huston L, James E, Kwok W . Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol. 2008; 180(3):1758-68. PMC: 3373268. DOI: 10.4049/jimmunol.180.3.1758. View

Quan F, Huang C, Compans R, Kang S . Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007; 81(7):3514-24. PMC: 1866067. DOI: 10.1128/JVI.02052-06. View

Yen H, Webster R . Pandemic influenza as a current threat. Curr Top Microbiol Immunol. 2009; 333:3-24. DOI: 10.1007/978-3-540-92165-3_1. View

Lipatov A, Hoffmann E, Salomon R, Yen H, Webster R . Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis. 2006; 194(8):1040-3. DOI: 10.1086/507709. View

Lee L, Ha D, Simmons C, de Jong M, Vinh Chau N, Schumacher R . Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest. 2008; 118(10):3478-90. PMC: 2542885. DOI: 10.1172/JCI32460. View

Wood J, Robertson J . Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza Other Respir Viruses. 2009; 1(1):5-9. PMC: 4634662. DOI: 10.1111/j.1750-2659.2006.00003.x. View

Baras B, Stittelaar K, Kuiken T, Jacob V, Bernhard R, Giannini S . Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine. 2011; 29(11):2092-9. DOI: 10.1016/j.vaccine.2010.12.128. View

Goy K, Von Bibra S, Lewis J, Laurie K, Barr I, Anderson D . Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza. Influenza Other Respir Viruses. 2009; 2(4):115-25. PMC: 4634225. DOI: 10.1111/j.1750-2659.2008.00046.x. View

Lin J, Li C, Wang X, Su N, Liu Y, Qiu Y . Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J Infect Dis. 2008; 199(2):184-7. DOI: 10.1086/595832. View

10.

Govorkova E, Webby R, Humberd J, Seiler J, Webster R . Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis. 2006; 194(2):159-67. DOI: 10.1086/505225. View

11.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

12.

Abelin A, Colegate T, Gardner S, Hehme N, Palache A . Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine. 2010; 29(6):1135-8. DOI: 10.1016/j.vaccine.2010.11.042. View

13.

LaMere M, Lam H, Moquin A, Haynes L, Lund F, Randall T . Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol. 2011; 186(7):4331-9. PMC: 3159153. DOI: 10.4049/jimmunol.1003057. View

14.

Xu X, Subbarao , Cox N, Guo Y . Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology. 1999; 261(1):15-9. DOI: 10.1006/viro.1999.9820. View

15.

Stephenson I, Bugarini R, Nicholson K, Podda A, Wood J, Zambon M . Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis. 2005; 191(8):1210-5. DOI: 10.1086/428948. View

16.

Goji N, Nolan C, Hill H, Wolff M, Noah D, Williams T . Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis. 2008; 198(5):635-41. DOI: 10.1086/590916. View

17.

Nguyen H, van Ginkel FW , Vu H, McGhee J, Mestecky J . Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis. 2001; 183(3):368-76. DOI: 10.1086/318084. View

18.

. Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerg Infect Dis. 2008; 14(7):e1. PMC: 2600337. DOI: 10.3201/eid1407.071681. View

19.

Middleton D, Rockman S, Pearse M, Barr I, Lowther S, Klippel J . Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol. 2009; 83(15):7770-8. PMC: 2708649. DOI: 10.1128/JVI.00241-09. View

20.

Hoschler K, Gopal R, Andrews N, Saville M, Pepin S, Wood J . Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains. Influenza Other Respir Viruses. 2009; 1(5-6):199-206. PMC: 4941882. DOI: 10.1111/j.1750-2659.2007.00033.x. View